| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Industry press release |
| Population | Men |
| Source | Marius Pharmaceuticals (GlobeNewswire release via Santé log) |
| URL | santelog.com/actualites-sante-nasdaq/new-research-marius-pharmaceuticals-reveals-major-mens-health-awareness-gap (opens in a new tab) |
Specific Claim Evaluated
75% of men aged 40 to 65 reported at least 1 symptom commonly linked to testosterone deficiency, and every man should have his testosterone levels checked.
Primary Research Supporting or Contradicting the Claim
Guidelines recommend against routine screening of men in the general population (Bhasin et al., 2018). Symptomatic androgen deficiency affects about 5.6% of men aged 30 to 79 years (Araujo et al., 2007).
Corrected Evidence-Based Interpretation
Symptoms such as fatigue, poor sleep and low motivation are common and nonspecific. Testosterone testing is indicated for men with consistent symptoms and signs, not for all men.
Rationale for Grade
The release counts nonspecific symptoms as indicators of testosterone deficiency and uses them to support universal testing, a recommendation contrary to guidelines. The survey was commissioned by a manufacturer of testosterone therapy.
References
- Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-4247. PMID
Supporting excerpt: "Crude prevalence of symptomatic androgen deficiency was 5.6%" - Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs"